Compare Cassava Sciences Inc (FLNA) vs Uber Technologies Inc (UBER) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

Uber Technologies (UBER) trades at $72.08, down 2.94% today, amid bearish technical signals despite strong fundamentals. The company reported robust 2025 results with $52.02B revenue and $10.05B net income, though 2026 projections show moderating growth. Recent news highlights strategic shifts toward autonomous vehicles with robotaxi pilots in Madrid and Munich, alongside cost-cutting measures including HR layoffs. Analyst consensus remains strongly bullish with an $108.92 price target, representing 51% upside potential from current levels.

Uber presents a compelling growth story with expanding profitability and market dominance, though near-term technical weakness and moderating 2026 earnings projections warrant caution. The autonomous vehicle expansion represents significant long-term opportunity, while competitive pressures and regulatory risks persist. With zero sell ratings and overwhelming analyst support, the stock appears fundamentally undervalued despite current bearish technical indicators.